The Overview of Japanese Generic Drug Market ver.2016
SKU:
$480.00
$480.00
per item
This report talks about the overview of Japanese generic drug market. The readers will understand overall climate surrounding generic market in Japan. The report covers related regulations, generics's share in Japan, market size, primary makers, market trend, and updated situation about biosimilars and authorized generics.
The share of generics in the prescription drugs market has been dramatically increasing in terms of both volume and value. The recent volume share was 60.1% in the 2nd quarter in 2016. This increase has been particularly pronounced since 2007 due to government measures devised to increase the use of generics.
The market size for generics in 2015 is estimated about 789.7 billion JPY. This was about 12% of the prescription drugs market as a whole. The generics market is estimated to grow to around 1,117 billion JPY in 2018.
The market has expanded in recent years thanks to government promotion of generics. Also, dynamic activity has been seen from foreign generics companies and new drug manufacturers. Although the impact has not been particularly great, new drug manufacturers such as Pfizer have begun full-scale entry into the generics market.
Promotion of generics drug prescriptions in medical institutions has been gradually increasing, with Diagnosis Procedure Combination (DPC)iii hospitals leading the way. DPC hospitals use a daily comprehensive payment system based on diagnostic group classification. The 2014 Medical Fee Revision added new generic drug coefficients. Since medical facilities can receive higher coefficients for more usage of generics, generic drug prescription is expected to increase in these hospitals.
Dispensing pharmacies had not been proactive with generic prescriptions in the past, however, government pressure has led to an accelerated increase in generic drug promotion, becoming a major driving force in the market rising.
The market size for generics in 2015 is estimated about 789.7 billion JPY. This was about 12% of the prescription drugs market as a whole. The generics market is estimated to grow to around 1,117 billion JPY in 2018.
The market has expanded in recent years thanks to government promotion of generics. Also, dynamic activity has been seen from foreign generics companies and new drug manufacturers. Although the impact has not been particularly great, new drug manufacturers such as Pfizer have begun full-scale entry into the generics market.
Promotion of generics drug prescriptions in medical institutions has been gradually increasing, with Diagnosis Procedure Combination (DPC)iii hospitals leading the way. DPC hospitals use a daily comprehensive payment system based on diagnostic group classification. The 2014 Medical Fee Revision added new generic drug coefficients. Since medical facilities can receive higher coefficients for more usage of generics, generic drug prescription is expected to increase in these hospitals.
Dispensing pharmacies had not been proactive with generic prescriptions in the past, however, government pressure has led to an accelerated increase in generic drug promotion, becoming a major driving force in the market rising.